Blastic Plasmacytoid Dendritic Cell Neoplasm clinical trials at UCLA
3 in progress, 1 open to eligible people
SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS
open to eligible people ages 18-74
This is an open-label study of the safety, biodynamics, and anti-cancer activity of SENTI-202 (an off-the-shelf logic gated CAR NK cell therapy) in patients with CD33 and/or FLT3 expressing blood cancers, including AML and MDS.
Los Angeles 5368361, California 5332921 and other locations
Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Sorry, in progress, not accepting new patients
This study will evaluate the safety, tolerability, and efficacy of Orca-T, an allogeneic stem cell and T-cell immunotherapy biologic manufactured for each patient (transplant recipient) from the mobilized peripheral blood of a specific, unique donor. It is composed of purified hematopoietic stem and progenitor cells (HSPCs), purified regulatory T cells (Tregs), and conventional T cells (Tcons) in participants undergoing myeloablative allogeneic hematopoietic cell transplant transplantation for hematologic malignancies.
Los Angeles 5368361, California 5332921 and other locations
IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN
Sorry, in progress, not accepting new patients
This is an open-label, multi-center, Phase 1/2 study to determine the MTD and assess the safety, tolerability, PK, immunogenicity, and anti-leukemia activity of IMGN632 when administered as monotherapy to patients with CD123+ disease.
Los Angeles 5368361, California 5332921 and other locations
Our lead scientists for Blastic Plasmacytoid Dendritic Cell Neoplasm research studies include Gary J. Schiller, MD.
Last updated: